About Avadel Pharmaceuticals
Avadel Pharmaceuticals is a publicly listed company based in Dublin (Ireland) founded in 1990, and was acquired by Alkermes in October 2025. Proprietary drug delivery technologies and narcolepsy treatments are developed. It operates in the Healthcare and Technology sectors. The company has 188 employees. Avadel Pharmaceuticals has completed 1 acquisition, including Eclat Pharmaceuticals. Its chief executive, as recorded, is Gregory J Divis. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science.
Company details
Pharma company with proprietary drug delivery tools and drugs for narcolepsy. The company is involved in the development of its lead candidate FT218, which is a once nightly formulation of sodium oxybate designed to treat narcolepsy sleeping disorder. The company is also involved in commercialized some hospital (mainly injectables) and pediatric (oral formulations) care products. The company offers 4 main drug delivery technologies - micropump (precisely delayed drug release microcapsules), liquitime (oral liquid formulation with delayed-release formulation), triggerlock (a mechanism to prevent abuse in opiate analgesics), and medusa (hydrogel depot formulation for subcutaneous injections).
- Headquarters Dublin, Ireland
- Employees 188
- Stage Public
- SectorsHealthcareTechnology
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website avadel.com
- Social LinkedIn X Facebook
- Acquired by Alkermes (Oct 2025)
- Legal Name Avadel Pharmaceuticals Plc
- Annual Revenue$169.12 M (USD)504.79as on Dec 31, 2024
- Net Profit-$48.83 M (USD)69.53as on Dec 31, 2024
- EBITDA-$39.72 M (USD)70.81as on Dec 31, 2024
- Latest Funding Round$117.4M (USD), Post-IPO
Mar 2022
- InvestorsAlkermes
& 5 more
- Employee Count188
- Investments & Acquisitions
- Acquired byAlkermes
(Oct 2025)
Funding Insights of Avadel Pharmaceuticals
- Total Rounds 3
- Last Round Post-IPO — $117.4M
- First Round $143.7M
(Mar 2018)
- Investors Count 5
All 3 funding rounds of Avadel Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $117.4M | Post-IPO | – | – | – |
| Feb 2020 | $65M | Post-IPO | – | – | |
| Mar 2018 | $143.7M | Debt – Conventional | – | – | – |
6 investors in total: 6 institutional.
Investors in Avadel Pharmaceuticals
Avadel Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Alkermes, RTW Investments and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Venture capital fund focused on biotechnology startups | avorocapital.com | New York, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Provides financial investments to healthcare firms for health and well-being innovation. | 2015 | acutacapital.com | Belmont, United States | |
Developer of small molecule therapeutics and drug delivery technologies for multiple CNS diseases | 1987 | alkermes.com | Dublin, Ireland |
Investor details for Avadel Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avadel Pharmaceuticals
71 people are tracked at Avadel Pharmaceuticals (31 in leadership, 5 in board & advisors, 35 in team); the tracked headcount is 188.
| Name | Role | Group |
|---|---|---|
Gregory J Divis | CEO | Leadership |
Thomas S. McHugh | Chief Financial Officer | Leadership |
Tara Margarella, DO | Sr. Medical Director | Leadership |
Ryan Glover | Regional Business Director | Leadership |
Yvonne Clark | Vice President & Associate General Counsel, Compliance | Leadership |
William (BJ) Schaefer | Director Of Technical Operations | Leadership |
Rosemarie Tully | VP & General Manager, Europe | Leadership |
Jennifer Gudeman | VP, Medical & Clinical Affairs | Leadership |
Angie Woods | VP, People & Culture | Leadership |
Kevin Springman | Vp, Sales & Commercial Operations | Leadership |
Brenna Kates | Sr. Director, Patient/Consumer Marketing | Leadership |
Patty Pound | Vice President Marketing | Leadership |
Monica M. Pierre | Regional Business Director | Leadership |
Charles Mosseri Marlio | Director of Strategic Planning and Investor Relations | Leadership |
David W. | National Account Director | Leadership |
Monica Pierre | Regional Business Director | Leadership |
april zambetti | Associate Director Sales Training | Leadership |
Anne Koch | Director Of Supply Chain | Leadership |
Thorsteinn Thorsteinsson | Executive Director Product Development | Leadership |
Craig Siman | Executive Director, Legal Affairs | Leadership |
51 more people are available in the full profile.
Complete people profiles for Avadel Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avadel Pharmaceuticals
Avadel Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AVDL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Jun 1996
- Listed onNASDAQ: AVDL
- Listed entityAvadel Pharmaceuticals plc
- Exchange sectorHealth technology
- ISINIE00BDGMC594
- Share price$21.64 (+0.05% on the day) · 2026-02-13
- Market capitalisation$2.12B
- EPS (diluted, trailing year)$-0.01
- Volume (last session)35,016,325
- Analyst consensusNeutral
Financials of Avadel Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $169.1M | -$48.8M | -$39.7M |
| 2023 | $28.0M | -$160.3M | -$136.1M |
| 2022 | -$137.5M | -$93.7M | |
| 2021 | -$77.3M | -$84.8M | |
| 2020 | $22.3M | $7.0M | -$35.0M |
Detailed financial statements for Avadel Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avadel Pharmaceuticals
Avadel Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eclat Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gasket sheets and sealing solutions are manufactured for industrial applications. | eclatpharma.com | Missouri, United States | 2010 | Mar 2012 | •••• |
Complete acquisition details for Avadel Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Avadel Pharmaceuticals
6 dated milestones of Avadel Pharmaceuticals across 35 years, from founding to its latest funding, stage changes and deals.
- Founded Avadel Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Eclat Pharmaceuticals.
- Funding First funding round of $143.7M.
- Funding Latest funding round, Post-IPO, of $117.4M.
- Exit Acquired by Alkermes.
Web traffic of Avadel Pharmaceuticals
The website of Avadel Pharmaceuticals (avadel.com) receives about 8K visits a month and ranks #1,705,741 among all websites worldwide, #2,307 in Biotechnology and Pharmaceuticals.
- Monthly visits8K
▼ 45.3% vs previous month
- Unique visitors6.3K
per month
- Global rank#1,705,741
among all websites
- Category rank#2,307
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.8
- Average visit1 min 16 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Avadel Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rhythmtx.com | 100% | 30.7K | #1,305,357 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avadel Pharmaceuticals
Complete news archive for Avadel Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avadel Pharmaceuticals
Avadel Pharmaceuticals was founded in 1990 and raised its 1st funding round 28 years after it was founded.
Avadel Pharmaceuticals is headquartered in Dublin, Ireland.
Gregory J Divis is the CEO of Avadel Pharmaceuticals, as recorded in our data.
Avadel Pharmaceuticals has 188 employees.
Annual revenue of Avadel Pharmaceuticals is $169.12M as on Dec 31, 2024.
Pharma company with proprietary drug delivery tools and drugs for narcolepsy. The company is involved in the development of its lead candidate FT218, which is a once nightly formulation of sodium oxybate designed to treat narcolepsy sleeping disorder. The company is also involved in commercialized some hospital (mainly injectables) and pediatric (oral formulations) care products. The company offers 4 main drug delivery technologies - micropump (precisely delayed drug release microcapsules), liquitime (oral liquid formulation with delayed-release formulation), triggerlock (a mechanism to prevent abuse in opiate analgesics), and medusa (hydrogel depot formulation for subcutaneous injections).
Yes, Avadel Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AVDL.
Avadel Pharmaceuticals has made 1 acquisition, including Eclat Pharmaceuticals.
Avadel Pharmaceuticals has 6 investors. Key investors include Alkermes, RTW Investments, Vivo Capital, Avoro Capital Advisors, and Acuta Capital Partners.
Yes. Avadel Pharmaceuticals was acquired by Alkermes in October 2025.